S&P 500   4,438.94 (-0.37%)
DOW   34,891.38 (+0.27%)
QQQ   369.48 (-1.03%)
AAPL   145.07 (-1.26%)
MSFT   293.57 (-1.93%)
FB   351.46 (-0.42%)
GOOGL   2,816.32 (-0.98%)
TSLA   796.48 (+2.85%)
AMZN   3,373.84 (-1.51%)
NVDA   215.76 (-2.29%)
BABA   148.72 (+2.51%)
NIO   36.51 (+3.19%)
CGC   14.65 (+5.32%)
GE   105.90 (+2.02%)
MU   75.28 (+1.66%)
AMD   107.30 (+1.42%)
T   27.55 (+1.55%)
F   14.25 (+3.41%)
ACB   6.35 (+6.72%)
DIS   179.00 (+1.70%)
PFE   43.73 (-0.48%)
BA   226.20 (+2.17%)
BAC   43.34 (+2.85%)
S&P 500   4,438.94 (-0.37%)
DOW   34,891.38 (+0.27%)
QQQ   369.48 (-1.03%)
AAPL   145.07 (-1.26%)
MSFT   293.57 (-1.93%)
FB   351.46 (-0.42%)
GOOGL   2,816.32 (-0.98%)
TSLA   796.48 (+2.85%)
AMZN   3,373.84 (-1.51%)
NVDA   215.76 (-2.29%)
BABA   148.72 (+2.51%)
NIO   36.51 (+3.19%)
CGC   14.65 (+5.32%)
GE   105.90 (+2.02%)
MU   75.28 (+1.66%)
AMD   107.30 (+1.42%)
T   27.55 (+1.55%)
F   14.25 (+3.41%)
ACB   6.35 (+6.72%)
DIS   179.00 (+1.70%)
PFE   43.73 (-0.48%)
BA   226.20 (+2.17%)
BAC   43.34 (+2.85%)
S&P 500   4,438.94 (-0.37%)
DOW   34,891.38 (+0.27%)
QQQ   369.48 (-1.03%)
AAPL   145.07 (-1.26%)
MSFT   293.57 (-1.93%)
FB   351.46 (-0.42%)
GOOGL   2,816.32 (-0.98%)
TSLA   796.48 (+2.85%)
AMZN   3,373.84 (-1.51%)
NVDA   215.76 (-2.29%)
BABA   148.72 (+2.51%)
NIO   36.51 (+3.19%)
CGC   14.65 (+5.32%)
GE   105.90 (+2.02%)
MU   75.28 (+1.66%)
AMD   107.30 (+1.42%)
T   27.55 (+1.55%)
F   14.25 (+3.41%)
ACB   6.35 (+6.72%)
DIS   179.00 (+1.70%)
PFE   43.73 (-0.48%)
BA   226.20 (+2.17%)
BAC   43.34 (+2.85%)
S&P 500   4,438.94 (-0.37%)
DOW   34,891.38 (+0.27%)
QQQ   369.48 (-1.03%)
AAPL   145.07 (-1.26%)
MSFT   293.57 (-1.93%)
FB   351.46 (-0.42%)
GOOGL   2,816.32 (-0.98%)
TSLA   796.48 (+2.85%)
AMZN   3,373.84 (-1.51%)
NVDA   215.76 (-2.29%)
BABA   148.72 (+2.51%)
NIO   36.51 (+3.19%)
CGC   14.65 (+5.32%)
GE   105.90 (+2.02%)
MU   75.28 (+1.66%)
AMD   107.30 (+1.42%)
T   27.55 (+1.55%)
F   14.25 (+3.41%)
ACB   6.35 (+6.72%)
DIS   179.00 (+1.70%)
PFE   43.73 (-0.48%)
BA   226.20 (+2.17%)
BAC   43.34 (+2.85%)
NASDAQ:EIGR

Eiger BioPharmaceuticals Stock Forecast, Price & News

$7.26
+0.26 (+3.71 %)
(As of 09/27/2021 12:44 PM ET)
Add
Compare
Today's Range
$6.99
$7.30
50-Day Range
$7.00
$9.10
52-Week Range
$6.80
$13.49
Volume2,146 shs
Average Volume212,868 shs
Market Capitalization$246.48 million
P/E RatioN/A
Dividend YieldN/A
Beta1.34
30 days | 90 days | 365 days | Advanced Chart
Receive EIGR News and Ratings via Email

Sign-up to receive the latest news and ratings for Eiger BioPharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Eiger BioPharmaceuticals logo

About Eiger BioPharmaceuticals

Eiger BioPharmaceuticals, Inc. engages in the development and commercialization of foundational therapies for Hepatitis Delta Virus. It is also developing avexitide as a treatment for Post-Bariatric Hypoglycemia. The company was founded by David A. Cory and Glenn S. Jeffrey on November 6, 2008 and is headquartered in Palo Alto, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EIGR
Employees
28
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$2.92 per share

Profitability

Net Income
$-65,050,000.00

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$246.48 million
Next Earnings Date
11/4/2021 (Estimated)
Optionable
Not Optionable

MarketRank

Overall MarketRank

2.14 out of 5 stars

Medical Sector

415th out of 1,352 stocks

Biological Products, Except Diagnostic Industry

66th out of 195 stocks

Analyst Opinion: 3.5Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












Eiger BioPharmaceuticals (NASDAQ:EIGR) Frequently Asked Questions

Is Eiger BioPharmaceuticals a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eiger BioPharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Eiger BioPharmaceuticals stock.
View analyst ratings for Eiger BioPharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Eiger BioPharmaceuticals?

Wall Street analysts have given Eiger BioPharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Eiger BioPharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Eiger BioPharmaceuticals' next earnings date?

Eiger BioPharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Eiger BioPharmaceuticals
.

How were Eiger BioPharmaceuticals' earnings last quarter?

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) announced its quarterly earnings data on Thursday, August, 5th. The biotechnology company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.54) by $0.03.
View Eiger BioPharmaceuticals' earnings history
.

How has Eiger BioPharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Eiger BioPharmaceuticals' stock was trading at $6.81 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, EIGR shares have increased by 6.5% and is now trading at $7.25.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for EIGR?

4 brokerages have issued 1-year price objectives for Eiger BioPharmaceuticals' shares. Their forecasts range from $22.00 to $45.00. On average, they expect Eiger BioPharmaceuticals' share price to reach $30.50 in the next year. This suggests a possible upside of 320.7% from the stock's current price.
View analysts' price targets for Eiger BioPharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Eiger BioPharmaceuticals' key executives?

Eiger BioPharmaceuticals' management team includes the following people:
  • David A. Cory, President, Chief Executive Officer & Director
  • Sriram Ryali, Chief Financial Officer
  • Ingrid C. Choong, Senior Vice President-Clinical Development
  • Colin Hislop, Senior VP-Clinical & Development Operations
  • Chris Dadas, Vice President-Medical Affairs

What other stocks do shareholders of Eiger BioPharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eiger BioPharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Gilead Sciences (GILD), Skyworks Solutions (SWKS), ZIOPHARM Oncology (ZIOP), Amarin (AMRN), Celldex Therapeutics (CLDX), Catalyst Pharmaceuticals (CPRX), Exelixis (EXEL), SCYNEXIS (SCYX) and Sangamo Therapeutics (SGMO).

What is Eiger BioPharmaceuticals' stock symbol?

Eiger BioPharmaceuticals trades on the NASDAQ under the ticker symbol "EIGR."

Who are Eiger BioPharmaceuticals' major shareholders?

Eiger BioPharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include 683 Capital Management LLC (8.69%), BlackRock Inc. (7.29%), Vanguard Group Inc. (4.96%), Geode Capital Management LLC (1.76%), State Street Corp (1.60%) and Goldman Sachs Group Inc. (1.22%). Company insiders that own Eiger BioPharmaceuticals stock include Eldon C Mayer III, Evan Loh, Jeffrey S Glenn and Thomas John Dietz.
View institutional ownership trends for Eiger BioPharmaceuticals
.

Which institutional investors are selling Eiger BioPharmaceuticals stock?

EIGR stock was sold by a variety of institutional investors in the last quarter, including Laurion Capital Management LP, Goldman Sachs Group Inc., Renaissance Technologies LLC, Susquehanna International Group LLP, Russell Investments Group Ltd., BlackRock Inc., Northern Trust Corp, and Citadel Advisors LLC. Company insiders that have sold Eiger BioPharmaceuticals company stock in the last year include Eldon C Mayer III, and Evan Loh.
View insider buying and selling activity for Eiger BioPharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Eiger BioPharmaceuticals stock?

EIGR stock was bought by a variety of institutional investors in the last quarter, including 683 Capital Management LLC, Bridgeway Capital Management LLC, Morgan Stanley, Morgan Stanley, Vanguard Group Inc., GSA Capital Partners LLP, Caxton Corp, and Geode Capital Management LLC. Company insiders that have bought Eiger BioPharmaceuticals stock in the last two years include Eldon C Mayer III, Jeffrey S Glenn, and Thomas John Dietz.
View insider buying and selling activity for Eiger BioPharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Eiger BioPharmaceuticals?

Shares of EIGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eiger BioPharmaceuticals' stock price today?

One share of EIGR stock can currently be purchased for approximately $7.25.

How much money does Eiger BioPharmaceuticals make?

Eiger BioPharmaceuticals has a market capitalization of $246.14 million. The biotechnology company earns $-65,050,000.00 in net income (profit) each year or ($2.31) on an earnings per share basis.

How many employees does Eiger BioPharmaceuticals have?

Eiger BioPharmaceuticals employs 28 workers across the globe.

What is Eiger BioPharmaceuticals' official website?

The official website for Eiger BioPharmaceuticals is www.eigerbio.com.

Where are Eiger BioPharmaceuticals' headquarters?

Eiger BioPharmaceuticals is headquartered at 2155 PARK BOULEVARD, PALO ALTO CA, 94306.

How can I contact Eiger BioPharmaceuticals?

Eiger BioPharmaceuticals' mailing address is 2155 PARK BOULEVARD, PALO ALTO CA, 94306. The biotechnology company can be reached via phone at (650) 272-6138 or via email at [email protected].


This page was last updated on 9/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.